Roche Diagnostics launches cobas e 411 immunoassay analyzer
Indianapolis, USA. Roche Diagnostics has released its next generation
bench-top immunoassay analyzer, the cobas e 411 aimed at the low- to mid-
volume immunoassay market.
"Roche Diagnostics is committed to being the
leader in the immunoassay market. The cobas e 411 analyzer is evidence of
our strength in innovation to provide greater efficiency and increased
productivity in the laboratory," said Andy Thomson, Senior Vice President
and General Manager, Roche Centralized Diagnostics.
The cobas e 411
analyzer can operate independently, as a dedicated STAT analyzer, or as part
of a networked clinical laboratory environment. It provides results for
critical assays — Troponin T, CK-MB, Myoglobin, and HCG — in as little as
nine minutes. It uses electrochemiluminescence (ECL) to deliver low-end
sensitivity and a broad dynamic range. It virtually eliminates unnecessary
repeats and reruns, providing accurate results the first time.
platform has a standardized graphical user-interface, common assay
applications and technologies, and uniform reagent carriers across